|
| Monday, April 26, 2021 |
|
|
泰诺麦博宣布完成4.5亿元人民币A轮融资 |
| 近日，珠海泰诺麦博生物技术有限公司（Trinomab Biotech Co., Ltd. 简称“泰诺麦博”或“Trinomab”）宣布完成4.5亿元人民币的A轮融资，此次融资由高瓴创投领投，康哲药业、药明生物产业基金、无锡国联等共同参与完成。 more info >> |
|
| Monday, April 5, 2021 |
|
|
China Medical System (0867.HK) Accelerating Development and Stepping to New Heights, Driven by Innovation |
| As the earning season approaches, once again listed pharmaceutical companies are attracting the attention of the public. Recently, China Medical System Holdings Limited ("CMS" or the "Company") has released its annual results, with both revenue and profit higher than market expectations. more info >> |
|
| Tuesday, March 30, 2021 |
|
|
China Medical System (0867) Ushers in a Revaluation with its Continuous Growth and Synergy between Innovative Business and New Businesses |
Turnover and net profit increased at the same time, innovative pipeline continued to expand, and the synergy between its businesses became increasingly obvious .....China Medical System Limited (the "Company" or "CMS"), who has just released its annual results, has brought too many surprises to the market.
more info >> |
|
| Friday, February 5, 2021 |
|
|
China Medical System (0867.HK) Acquires a Dermatology Specialty Company: A Tough Player the Race |
| On February 1, China Medical System (0867.HK) announced that its subsidiary had acquired Luqa Ventures Co., Limited ("Luqa"), a dermatology specialty company. This acquisition expanded its product portfolio to include Luqa's dermatology products and marked the first foray into the medical aesthetic industry for China Medical System. more info >> |
|
| Monday, December 21, 2020 |
|
|
China Medical System (00867.HK) MSCI-ESG Rating Upgraded to AA, Reaching Global Level |
| Morgan Stanley Capital International (MSCI) issued a report on December 17 upgrading the ESG (Environmental, Social and Governance) Rating for China Medical System Holdings Limited ("China Medical System"), a well-established, innovation-driven specialty pharma with a focus on sales & marketing in China. more info >> |
|
| Thursday, August 13, 2020 |
|
|
China Medical System Holdings Limited 2020 Interim Results Announcement |
| China Medical System Holdings Limited ("CMS", or the "Company", SEHK:867), together with its subsidiaries (the "Group"), a well-established, innovation-driven specialty pharma with a focus on sales and marketing in China, announced its unaudited results for the 6 months ended 30 June 2020 ( the "Reporting Period"). more info >> |
|
| Friday, February 28, 2020 |
|
|
HY Medical AI and You'an Hospital join forces in the battle against NCP |
| Professor Li Hongjun, Chairman of the Professional Committee of Infectious Disease Radiology of the Chinese Medical Association Radiology Branch and Director of the Department of Radiology of You'an Hospital, along with members of the committee worked through the Spring Festival holidays, racing against time to launch the first "Handbook of Medical Imaging Diagnosis of NCP" (English and Chinese Edition). more info >> |
|
| Thursday, February 20, 2020 |
|
|
The Strength and Potential of China Medical System (867.HK) Reflected in an Untenable Short Selling Attack |
| 1. Targeted by a short seller, China Medical System fought back with a strong response and large-scale buyback more info >> |
|
| Friday, February 14, 2020 |
|
|
Blue Orca's Short Selling Plan Failed Because the Quality China Medical System (867.HK) Can Withstand Severe Tests |
| While the world attention is on the fight against Coronavirus in China, Blue Orca is concerned about other things at the same time. This time, this foreign short selling agency aimed at a high-quality Chinese pharmaceutical company. more info >> |
|
|
China Medical System (867.HK) Armed against Short Selling! The Biggest CSO Took Control of Full Industrial Chain |
| The short-selling company Blue Orca Capital would not have expected that its confrontation with China Medical System Holdings Limited ("China Medical System") actually helped the company. more info >> |
|
|
|
|
